Eli Lilly accepts committee recommendation to extend evacetrapib Phase 3 trial

Eli Lilly and Company has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months.



from The Medical News http://ift.tt/1Bub8Kg